Archive


Category: camidanlumab tesirine

  • EHA: ADC preps filings for Hodgkin lymphoma drug after ph2 readout

    ADC Therapeutics is looking to add a second approved antibody-drug conjugate to its portfolio after reporting strong phase 2 results with camidanlumab tesirine (cami) in relapsed/refractory Hodgkin lymphoma at the EHA annual meeting. In the study, 70% of patients treated with the CD25-targeting ADC had a response to therapy, with 33% of them having a […]